# Korro Bio, Inc. (KRRO) — capital_raise [announced]
Source: SEC API (secapi.ai) · situation sit_5d13e55611534b35f580 · retrieved 2026-08-12T07:21:55.278Z

## Overview
Korro Bio, Inc. is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases.

On August 5, 2026, Korro Bio, Inc. entered into an exchange agreement with entities affiliated with Venrock Healthcare Capital Partners. Under the agreement, Venrock surrendered an aggregate of 1,000,000 shares of Korro's common stock for no consideration, and Korro issued Venrock pre-funded warrants to purchase an aggregate of 1,000,000 shares of common stock with an exercise price of $0.001 per share and no expiration date. The pre-funded warrants are exercisable immediately and contain a beneficial ownership limitation of 9.99% (which may be increased or decreased to any other percentage not in excess of 19.99% at the holder's election upon 61 days' notice). Following the exchange, Korro had 13,725,646 shares of common stock issued and outstanding and unexercised pre-funded warrants to acquire 4,148,836 shares.

## Terms
- Counterparty: Venrock Healthcare Capital Partners · Consideration: stock · Price/share: $0.001

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001193125-26-336685): 8-K - Korro Bio, Inc. — *Korro Bio, Inc. is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases.* On August 5, 2026, Korro Bio, Inc. entered into an exchange agreement with entities affiliated with Venrock Healthcare Capital Partners. Under the agreement, Venrock surrendered an aggregate of 1,000,000 shares of Korro's common stock for no consideration, and Korro issued Venrock pre-funded warrants to purchase an aggregate of 1,000,000 shares of common stock with an exercise price of $0.001 per share and no expiration date. The pre-funded warrants are exercisable immediately and contain a beneficial ownership limitation of 9.99% (which may be increased or decreased to any other percentage not in excess of 19.99% at the holder's election upon 61 days' notice). Following the exchange, Korro had 13,725,646 shares of common stock issued and outstanding and unexercised pre-funded warrants to acquire 4,148,836 shares.
  https://www.sec.gov/Archives/edgar/data/1703647/0001193125-26-336685.txt

## Citations
- 0001193125-26-336685 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526336685